- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
- Home
- Our Research
- Clinical Trials
- Search Clinical Trials
Academic Institute
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
The purpose of this research study is to test the safety and effectiveness of docetaxel chemotherapy and pembrolizumab plus adenoviral-mediated interleukin-12 (ADV/IL-12) gene therapy in patients with anthracycline-refractory, triple negative br ... Read more >
Status: Enrolling
Investigator: Warren Ellsworth
Study Coordinator: Valentina Villarroel
Phone: 346.238.4384
This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
This is a non-inferiority randomized phase II trial investigating the efficacy and safety of 5FU/LV in combination with regorafenib for patients with metastatic colorectal cancer in the third-line setting. ... Read more >
Status: Enrolling
Investigator: Aldona Spiegel
Study Coordinator: Valentina Villarroel
Phone: 346.238.4384
This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >
Status: Enrolling
Investigator: Shilpan Shah
Study Coordinator: Britney Nguyen
Phone: 713.441.0685
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 (Part 1 [Dose Escalation] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Ph ... Read more >
Status: Open Not Enrolling
Investigator: Hanh Mai
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. ... Read more >
Status: Enrolling
Investigator: Pedro Ramirez
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evalua ... Read more >
Status: Open Not Enrolling
Investigator: Anaum Maqsood
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab. ... Read more >
Status: Open Not Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
The study evaluates the response to treatment with Ribociclib and Letrozole in patients with recurrent low grade serous cancer of the ovary, fallopian tube or peritoneum. ... Read more >
Status: Enrolling
Investigator: Behrouz Zand
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
Endometrial cancer (EC) is the most common gynaecological cancer. Current treatment of EC typically includes removal of the uterus and to determine the extent of the disease (removal of fallopian tubes, ovaries & if required a lymph node dissect ... Read more >
Status: Enrolling
Investigator: Kai Sun
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembro ... Read more >
Status: Open Not Enrolling
Investigator: Raj Satkunasivam
Study Coordinator: Taliah Muhammad
Phone: 346.238.4523
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder ... Read more >
Status: Open Not Enrolling
Investigator: Sandra Templeton
Study Coordinator: Juan Morales Viera
Phone: 786.803.2333
This is a prospective cohort study for patients diagnosed with ductal carcinoma in situ (DCIS) of the breast. The primary objective of the study is to create a de-identified database of patients, test results, treatment decisions and outcomes th ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet know ... Read more >
Status: Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
This is a Phase 3 Randomized, Controlled, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer. The primary e ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
The main purpose of this study is to learn if the usual chemotherapy given before surgery (neoadjuvant therapy) for breast cancer plus the experimental drug, atezolizumab, is better than the usual chemotherapy plus a placebo. (A placebo is a dru ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic). Drugs used in chemothera ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. ... Read more >
Status: Open Not Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab i ... Read more >
Status: Open Not Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Britney Nguyen
Phone: 713.441.0685
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexametha ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
The purpose of this study is to assess the safety and efficacy of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with ... Read more >
Status: Open Not Enrolling
Investigator: Kai Sun
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III hist ... Read more >
Status: Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.</div ... Read more >
Status: Enrolling
Investigator: Kai Sun
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitiv ... Read more >
Status: Open Not Enrolling
Investigator: Hanh Mai
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disea ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohis ... Read more >
Status: Enrolling
Investigator: Jun Zhang
Study Coordinator: Derek Cole
Phone: 713.441.5607
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KR ... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also ... Read more >
Status: Enrolling
Investigator: Pedro Ramirez
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 portion ... Read more >
Status: Enrolling
Investigator: Carrie Yuen
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
The purpose of the study is to compare CC-92480 (BMS-986348) with carfilzomib and dexamethasone (480Kd) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM. ... Read more >
Status: Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. ... Read more >
Status: Open Not Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
A single arm pilot study of 20 patients will be used to determine the feasibility of EA as a treatment for cancer survivors who have been treated with curative intent, but who have persistent CIPN for ?3 months after the cancer treatment is comp ... Read more >
Status: Open Not Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in diffe ... Read more >
Status: Open Not Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator:
Phone:
NCT049747319 Brief Summary: This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Beatriz Efron
Phone: 713.363.8890
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for ... Read more >
Status: Open Not Enrolling
Investigator: Shilpan Shah
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort) ... Read more >
Status: Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Elsie Rizk
Phone: 713.441.2557
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoemboli ... Read more >
Status: Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. ... Read more >
Status: Enrolling
Investigator: Kai Sun
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unre ... Read more >
Status: Enrolling
Investigator: Carrie Yuen
Study Coordinator: Britney Nguyen
Phone: 713.441.0685
This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treati ... Read more >
Status: Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
This phase II/III trial compares the effect of the combination of high-dose cisplatin every three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for the treatment of patients with locoregionally advanced head ... Read more >
Status: Open Not Enrolling
Investigator: Jenny Chang
Study Coordinator: Rabia Hashmani
Phone: 346.238.5894
Hormone receptor positive breast cancer HRBC is the most common cause of BC-related death. HRBC is characterized by a non-immunogenic microenvironment and consequently, modest responses have been observed with immune checkpoint blockade ICB alon ... Read more >
Status: Open Not Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3 ... Read more >
Status: Open Not Enrolling
Investigator: Sindhu Nair
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carbop ... Read more >
Status: Open Not Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
This is a open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of evorpacept (ALX148) + pembrolizumab + 5FU + platinum and of pembrolizumab + 5FU + platinum in patients with metastatic or unresectable, recurrent HNSCC who ... Read more >
Status: Open Not Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
This is a open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of evorpacept (ALX148) + pembrolizumab and of pembrolizumab alone in patients with metastatic or unresectable, recurrent HNSCC that is PD-L1 positive (CPS =1 ... Read more >
Status: Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
The study will investigate if a one month drug holiday from the CDK4/6 inhibitor drug, abemaciclib, will restore the body's sensitivity to the drug and make the subsequent treatment of abemaciclib plus fulvestrant more effective. ... Read more >
Status: Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Britney Nguyen
Phone: 713.441.0685
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell [CAR-T] therapy) for multiple myeloma. The ... Read more >
Status: Enrolling
Investigator: Anaum Maqsood
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choi ... Read more >
Status: Enrolling
Investigator: Hanh Mai
Study Coordinator: Natolie Hamilton
Phone: 469.267.9275
This phase III clinical trial will evaluate the impact on survival of adding chaplain-provided spiritual care or psychotherapy/meditation to standard-of-care (SOC) and palliative measures, plus chemotherapy if recommended, and comparing it with ... Read more >
Status: Open Not Enrolling
Investigator: Jun Zhang
Study Coordinator: Derek Cole
Phone: 713.441.5607
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such ... Read more >
Status: Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). ... Read more >
Status: Enrolling
Investigator: Pedro Ramirez
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemo ... Read more >
Status: Open Not Enrolling
Investigator: Tarrik Zaid
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. ... Read more >
Status: Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
This is a Phase I/Ib study testing the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer. Cancer cells grow in an uncontrolled manner and this c ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer. ... Read more >
Status: Open Not Enrolling
Investigator: Nestor Esnaola
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the body (non-metasta ... Read more >
Status: Open Not Enrolling
Investigator: Maen Abdelrahim
Study Coordinator: Elsie Rizk
Phone: 713.441.2557
We propose a regimen of six months neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcome ... Read more >
Status: Enrolling
Investigator: Nestor Esnaola
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
Neoadjuvant FOLFIRINOX combined with Pembrolizumab followed by surgery for patients with resectable pancreatic cancer Trial Phase: Phase II Clinical Indication: Pancreatic ductal adenocarcinoma; Adenocarcinoma; AJCC I, II, or III; 1st Line neoa ... Read more >
Status: Open Not Enrolling
Investigator: Kumar Pichumani
Study Coordinator: Kumar Pichumani
Phone: 713.441.7190
Title: Investigation of central nervous system tumor metabolism in patients undergoing surgical resection PI- Kumar Pichumani, PhD coPI- David Baskin, MD Interest in the clinical potential of tumor intermediary metabolism dates to the 19 ... Read more >
Status: Open Not Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
The study is an open-label, randomized, phase III trial to evaluate the addition of atezolizumab to standard chemoradiation for limited stage small cell lung cancer. Patients will be enrolled and randomized 1:1 between chemoradiation + atezolizu ... Read more >
Status: Open Not Enrolling
Investigator: David Baskin
Study Coordinator: Helga Jones
Phone: 713.363.9388
" Purpose The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site p ... Read more >
Status: Open Not Enrolling
Investigator: Siddhartha Ganguly
Study Coordinator: Britney Nguyen
Phone: 713.441.0685
A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma. ... Read more >
Status: Open Not Enrolling
Investigator: Eleni Efstathiou
Study Coordinator: Derek Cole
Phone: 713.441.5607
This is a phase 2 open label single arm study using an external control arm, to assess if the addition of darolutamide to ADT provides superior efficacy in terms of progression-free survival (PFS), as compared to ADT alone for men diagnosed with ... Read more >
Status: Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene ... Read more >
Status: Enrolling
Investigator: Monisha Singh
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers. Palbociclib and binimetinib are both in a class of medications called kinase inhibitors. They work ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer (EBC). ... Read more >
Status: Enrolling
Investigator: Kai Sun
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with ... Read more >
Status: Enrolling
Investigator: Monisha Singh
Study Coordinator: Safiya Joseph
Phone: 203.308.8567
To evaluate the efficacy and safety of tebentafusp-based regimens tebentafusp monotherapy and in combination with anti-PD1) vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care ( ... Read more >
Status: Enrolling
Investigator: Jun Zhang
Study Coordinator: Derek Cole
Phone: 713.441.5607
The goal of this research study is to find the highest, safest dose of honokiol (a type of dietary supplement) that can be given to patients who have resectable early-stage NSCLC. Researchers also want to learn if giving honokiol before surger ... Read more >
Status: Open Not Enrolling
Investigator: Jun Zhang
Study Coordinator: Derek Cole
Phone: 713.441.5607
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >
Status: Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Milan Sheth
Phone: 713.790.3311
This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination therapy using All-Trans Retinoic Acid (ATRA) with Carfilzomib based therapies in plasma cell myeloma also commonly referred as Multiple Myelom ... Read more >
Status: Open Not Enrolling
Investigator: Eleni Efstathiou
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolle ... Read more >
Status: Enrolling
Investigator: David Baskin
Study Coordinator: Melissa Daly
Phone: 713.441.3834
NCT03603405 This is a prospective, phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy for anaplastic astrocytoma (AA) or glioblastoma mul ... Read more >
Status: Enrolling
Investigator: David Baskin
Study Coordinator: Melissa Daly
Phone: 713.441.3834
NCT03596086 This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy in recurrent anaplastic astrocytoma or glioblastoma ... Read more >
Status: Open Not Enrolling
Investigator: Eleni Efstathiou
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. ... Read more >
Status: Open Not Enrolling
Investigator: Chinemerem Abanonu
Study Coordinator: Frances Saubon
Phone: 713.624.0724
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvemen ... Read more >
Status: Open Not Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Alexys Brock
Phone: 346.238.4814
This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens. ... Read more >
Status: Enrolling
Investigator: Pedro Ramirez
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune s ... Read more >
Status: Open Not Enrolling
Investigator: Sai ravi kiran Pingali
Study Coordinator: Natolie Hamilton
Phone: 469.267.9275
This is a laboratory-based study supported by NIH funding. It is aimed to explore the therapeutic effects of novel molecules or antigens to treat hematologic diseases. In order to complete these studies, samples including peripheral blood, bone ... Read more >
Status: Open Not Enrolling
Investigator: Sindhu Nair
Study Coordinator: Misbah Baloch
Phone: 713.790.3311
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER) ... Read more >
Status: Enrolling
Investigator: Eleni Efstathiou
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer. ... Read more >
Status: Open Not Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Soli ... Read more >
Status: Open Not Enrolling
Investigator: Raj Satkunasivam
Study Coordinator: Taliah Muhammad
Phone: 346.238.4523
Primary Purpose: Treatment ... Read more >
Status: Enrolling
Investigator: Jun Zhang
Study Coordinator: Gabrielle Hayes
Phone: 734.415.918
Livmoniplimab is an investigational drug being developed for the treatment of NSCLC. There are 2 stages to this study. In Stage 1, there are 4 treatment arms. Participants will either receive livmoniplimab (at different doses) in combination wit ... Read more >
Status: Open Not Enrolling
Investigator: Polly Niravath
Study Coordinator: Kelsey Banaglorioso
Phone: 346.238.5740
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exem ... Read more >
Status: Enrolling
Investigator: Bin Teh
Study Coordinator: Natolie Hamilton
Phone: 469.267.9275
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiati ... Read more >
Status: Enrolling
Investigator: Aparna Kamat
Study Coordinator: Jaya Kamath
Phone: 713.441.6616
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumor ... Read more >
Status: Enrolling
Investigator: Shilpan Shah
Study Coordinator: Danielle Sewall
Phone: 346.238.2674
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with ... Read more >
Status: Open Not Enrolling
Investigator: Kai Sun
Study Coordinator: Jawairia Jawed
Phone: 346.356.3603
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trast ... Read more >